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Functional analysis of Ctf4 mutant alleles
Two proteins of disparate functions that bind Ctf4 are the GINS complex member and DNA replication protein Sld5, and Mms22, a subunit of an E3--ubiquitin ligase required for double strand break repair (Ben--Aroya et al. 2010; Duro et al. 2010; O'Donnell et al. 2010 ). We performed a yeast two--hybrid assay assessing the ability of the nine Ctf4 alleles to bind Sld5 and Mms22. As in published reports, the interaction between Ctf4 and Sld5 is sensitive to perturbation by mutation at all points tested except the extreme N--terminus (Gambus et al. 2009 ); on the other hand, the interaction between Ctf4 and Mms22 appears to be most sensitive to mutation or deletion in the middle third of the Ctf4 primary sequence ( Figure S2 ).
Knowing that there were differences in protein interactions between the Ctf4 alleles, we wanted to correlate phenotypic severity with the differing physical interactions. We first compared the sensitivity of the allele series to bleomycin, a radiomimetic that induces DNA double strand breaks, and HU ( Figure S2 ). Alleles that retained interactions with both Sld5 and Mms22 were not sensitive to genotoxic stress (i.e. ctf4--107 and ctf4--41). Conversely, alleles with disrupted Sld5 binding had a range of sensitivities from very subtle phenotypes in ctf4--154, to intermediate phenotypes in ctf4--46, --43 and --66 to null phenotypes in ctf4--25, --50 and --65 ( Figure S2C ). Binding to Mms22 did not predict a consistent trend in drug sensitivity. This experiment is complicated by the fact that the status of the many other Ctf4 physical interactions is unknown and the expression levels and protein stability of the various alleles are unknown. We quantitated the genome stability defects in each CTF4 allele first using a quantitative Chromosome Transmission Fidelity (CTF) assay ). While all alleles tested had a strong increase in chromosome loss, there were no significant differences between the alleles in this assay ( Table S6 ). The CTF method represents a sensitized assay in which the chromosome fragment is prone to loss and therefore may have prevented our identification of subtle differences between the alleles. We also performed a sister chromatid cohesion assay (Michaelis et al. 1997) . Again, all but one of the alleles had an elevated frequency of cells with separated chromatids similar to or greater than ctf4Δ ( Table S6 ). The presence of cohesion defects greater than ctf4Δ hints that some of the alleles may have dominant negative phenotypic effects. ctf4--41 exhibited lower rates of cohesion loss than the other mutants (Table S6) .
Interestingly, ctf4--41 was the only mutant protein that was able to physically interact with both Sld5 and Mms22 ( Figure S2 ).
Taken together, these data suggest that the ability to bind efficiently to Sld5 is critical to the cohesion establishment and genotoxin resistance functions Ctf4. Furthermore, the ability of a Ctf4 mutant protein to interact with Mms22 is predictive of neither its cohesion establishing ability, nor of its ability to function in the response to DNA damage.
Expanding the therapeutic target range of Ctf4/WDHD1 inhibitors
CTF4 is a genetic interaction hub connected to the yeast orthologs of CIN cancer genes (Yuen et al. 2007 ). Thus, Ctf4/WDHD1 represents a potential broad--spectrum target for anticancer therapeutic development. As genetic interaction data
is not yet available for a large proportion of the essential yeast genome, we sought to expand the range of genotypes targetable with potential inhibitors of Ctf4/WDHD1 by carrying out an SGA screen of Ctf4 against collections of essential gene mutants (Breslow et al. 2008; Li et al. 2011) . In addition to yielding candidate gene--drug target interactions, this approach also defines the potential off--target effects of Ctf4 inhibition by revealing the complement of cellular pathways sensitized to Ctf4 perturbation. Figure S3 shows the network of essential genes sensitized to CTF4 deletion. A handful of interactions were validated by tetrad analysis and spot--dilution assays (Table S5) . GO term analysis showed that the synthetic lethal partner set is enriched for genes involved in DNA replication, response to DNA damage, cell cycle progression, and mitotic spindle dynamics, all of which are consistent with previously described roles for Ctf4. Combining our data with previously published CTF4 genetic interactions for nonessential genes, we identified synthetic lethal interactions with numerous mutations that are recurrent in tumors (Table S7) . For example, ctf4Δ interacts negatively with mutations in the essential genes SMC1/MCD1, SMC3, CDC4, SCC2, SCC1/IRR1, and the nonessential gene MRE11 (this study and (McLellan et al. 2009 )), the human orthologs of which account for >15% of the mutational spectrum in colorectal cancer (Barber et al. 2008; Rajagopalan et al. 2004; Wang et al. 2004 ). Thus, CTF4 genetic interaction partners can be recurrently mutated in tumors, suggesting that a personalized, tumor genome sequencing--based approach to treatment could indicate whether a hypothetical Ctf4/WDHD1 inhibitor would be effective. We note that a mutation in a human ortholog of a CTF4 SL partner need not be causal in tumorigenesis to sensitize tumor cells to inhibition of Ctf4/WDHD1 function.
The SL interactions of cancer--gene orthologs with ctf4Δ presumably reflect a key deficiency in the replisome or DNA repair that is linked to the CTF4 deletion phenotype. Indeed, in another recent study we have confirmed by siRNA that depletion of CTF4/WDHD1 in human cancer cells sensitizes them to depletion of known cancer genes MRE11A, CDC4, cohesins or the Bloom's syndrome helicase, strongly supporting Ctf4 as a therapeutic target (van Pel et al., 2012) . Figure S2 Ctf4 is physically and functionally linked to several replication protein complexes. (A) Schematic of CTF4 alleles used. Numbers represent the amino acid number and asterisks indicate the relative position of point mutations. (B) CTF4 alleles confer differential ability to interact with Sld5 and Mms22 by yeast--two--hybrid. Cells carrying the indicated plasmids were grown to log phase, subjected to ten--fold serial dilution, plated on the indicated medium, and imaged after five days' growth. (C) CTF4 alleles confer differential sensitivity to DNA damaging drugs. Experiment was conducted as in (B) on plates containing the indicated drug and concentration. SPC110 TUB2 CMD1 TUB4 SPC29   ORC3   ACT1   SMC3   RFA3   CDC45   RPC34   MED4   TAF6   TAF5   CRM1   CDC23   STU2   YIF1  VTI1 SEC9 BOS1 YPT1 COG3 SEC2 LST8   POL5   POL30   ORC2   PRI1   POL3   DNA2   RFC4   MPS1   DAM1   RPC40   SPT15   SPN1   RPA190   TAP42   STU1   ULP1 PDS1 APC11 MCD1 APC5   CDC37  CDC11 GLC7 MOB2 CDC27   SEN1  RPS20  YHC1   EBP2   RFC5   PRI2   ECO1   MCM5   SLI15   SPC105   NOG2   YEF3   RPL32   FAL1   PRE2  SCL1  RPN6 RPT5  PRE5  RPT4  RPN5  RPN11  RPN7  PRE1  DBF4   CTF8   POL31   MCM7   RFC2   PSF1   CDC7   CDC8   ESS1  CNS1  RAP1  LCB2  YOR218C  SMT3   YLR317W (Table S5 ). Green edge, interaction did not validate by tetrad or spot dilution analysis. Red node, human ortholog appears in the cancer gene census. Tables S1-- 
